Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5501–5550 of 75391
On November 15, 2024, in relation to the retirement of Jim Stark from the Chief Financial Officer role, Mr. Stark and the Company entered into a Confidential Severance Agreement and Release
On November 15, 2024, M. Shane Bell notified the Board of Directors of First National Corporation (the “Company”) and its wholly-owned subsidiary, First Bank (the “Bank”), of his resignation as Executive Vice President and Chief Financial Officer of the Company and the Bank, effective December 2, 2024.
Effective November 12, 2024, Anne Townsend voluntarily resigned from her position as a member of the board of directors (the “Board”) of Rekor Systems, Inc. (the “Company”) in order to pursue personal commitments.
On November 14, 2024, each of Charles Austin, Saraswathy V. Nochur, Ph.D. and Sarah Noonberg, M.D., Ph.D., resigned from the Board of Directors of Marinus Pharmaceuticals, Inc. (the "Company") , effective immediately.
On November 14, 2024, each of Charles Austin, Saraswathy V. Nochur, Ph.D. and Sarah Noonberg, M.D., Ph.D., resigned from the Board of Directors of Marinus Pharmaceuticals, Inc. (the "Company") , effective immediately.
On November 14, 2024, each of Charles Austin, Saraswathy V. Nochur, Ph.D. and Sarah Noonberg, M.D., Ph.D., resigned from the Board of Directors of Marinus Pharmaceuticals, Inc. (the "Company") , effective immediately.
On November 11, 2024, Shawn Munsell gave notice of his resignation from his position as Chief Financial Officer of Calavo Growers, Inc. (“Calavo”), effective November 29, 2024.
On November 13, 2024, Dwight L. Merriman III, Co-Chairman and a member of the board of directors (the “Board”) of Ares Industrial Real Estate Income Trust Inc. (referred to herein as the “Company,” “we,” “our,” or “us”), notified the Company of his decision to retire from Ares Management Corporation and his position on the Board, effective as of February 1, 2025.
Pursuant to the Merger Agreement, effective as of the Effective Time, the position of each of Raymond W. Cohen, Alfred Ford, Jr., Kari L. Keese, Rinda K. Sama and John Woock, Ph.D., as an officer of the Company terminated.
Pursuant to the Merger Agreement, effective as of the Effective Time, each of Michael H. Carrel, Raymond W. Cohen, David M. Demski, Jane E. Kiernan, Esteban López, M.D., Robert E. McNamara, and Nancy L. Snyderman, M.D., FACS, comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the Effective Time, each of Michael H. Carrel, Raymond W. Cohen, David M. Demski, Jane E. Kiernan, Esteban López, M.D., Robert E. McNamara, and Nancy L. Snyderman, M.D., FACS, comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the Effective Time, the position of each of Raymond W. Cohen, Alfred Ford, Jr., Kari L. Keese, Rinda K. Sama and John Woock, Ph.D., as an officer of the Company terminated.
Pursuant to the Merger Agreement, effective as of the Effective Time, each of Michael H. Carrel, Raymond W. Cohen, David M. Demski, Jane E. Kiernan, Esteban López, M.D., Robert E. McNamara, and Nancy L. Snyderman, M.D., FACS, comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the Effective Time, the position of each of Raymond W. Cohen, Alfred Ford, Jr., Kari L. Keese, Rinda K. Sama and John Woock, Ph.D., as an officer of the Company terminated.
Pursuant to the Merger Agreement, effective as of the Effective Time, each of Michael H. Carrel, Raymond W. Cohen, David M. Demski, Jane E. Kiernan, Esteban López, M.D., Robert E. McNamara, and Nancy L. Snyderman, M.D., FACS, comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the Effective Time, the position of each of Raymond W. Cohen, Alfred Ford, Jr., Kari L. Keese, Rinda K. Sama and John Woock, Ph.D., as an officer of the Company terminated.
Pursuant to the Merger Agreement, effective as of the Effective Time, each of Michael H. Carrel, Raymond W. Cohen, David M. Demski, Jane E. Kiernan, Esteban López, M.D., Robert E. McNamara, and Nancy L. Snyderman, M.D., FACS, comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the Effective Time, each of Michael H. Carrel, Raymond W. Cohen, David M. Demski, Jane E. Kiernan, Esteban López, M.D., Robert E. McNamara, and Nancy L. Snyderman, M.D., FACS, comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof.
Pursuant to the Merger Agreement, effective as of the Effective Time, the position of each of Raymond W. Cohen, Alfred Ford, Jr., Kari L. Keese, Rinda K. Sama and John Woock, Ph.D., as an officer of the Company terminated.
Pursuant to the Merger Agreement, effective as of the Effective Time, each of Michael H. Carrel, Raymond W. Cohen, David M. Demski, Jane E. Kiernan, Esteban López, M.D., Robert E. McNamara, and Nancy L. Snyderman, M.D., FACS, comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof.
On November 12, 2024, the Company entered into an employment separation and release agreement (the “ Separation Agreement ”) with Laura Janney.
On November 11, 2024, Kye Chen and Grindr Inc. (the “Company”) announced that her final day as Chief Accounting Officer of the Company would be November 25, 2024.
On November 14, 2024, Curtiss-Wright Corporation (the “Company”) announced that Paul J. Ferdenzi, Vice President, General Counsel, and Corporate Secretary, will be retiring from the Company at year-end and stepping down from his positions as General Counsel and Corporate Secretary, effective November 13, 2024.
On November 11, 2024, Michael Kuta notified DMC Global Inc. (the “Company”) that he will retire as the Company’s President and Chief Executive Officer and as a member of the Board of Directors (the “Board”), in each case effective as of November 29, 2024 (the “Transition Date”).
On November 8, 2024, the Board of Directors (the “Board”) of SigmaTron International, Inc. (NASDAQ: SGMA), an electronic manufacturing services company (the “Company”), received notice that James J. Reiman, Chief Financial Officer of the Company, was resigning for personal reasons, effective November 8, 2024.
Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.
As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.
Effective as of November 8, 2024, Ms. Sabrina Mekhalfa left Cambium Networks Corporation ("Cambium" or the "Company") as Global Controller and Chief Accounting Officer (Principal Accounting Officer).
Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.
Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.
Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.
Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.
Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.
Dwight Soethout, Vice President-Chief Actuary, is the spouse of Ms. Strable and has been an employee of the Company since 1993. Mr. Soethout has indicated his intention to retire from the Company.
On November 12, 2024, Richard L. Greslick, Jr., Senior Executive Vice President, Chief Administrative Officer and Secretary of CNB Financial Corporation (the “Company”), informed the Company that he is resigning from all positions he holds with the Company, effective as of November 22, 2024.
Chad Verbowski will retire from Confluent, Inc. (“Confluent”) as Chief Technology Officer effective as of November 26, 2024, in order to take a career break.
On November 14, 2024 (the " Transition Date "), Mahesh Karande tendered his resignation as President and Chief Executive Officer and as a member of the Board of Directors (the " Board ") of the Company, effective immediately.
On November 13, 2024, John G. Morikis, Executive Chairman of the Board of Directors (the “Board”) of The Sherwin-Williams Company (“Sherwin-Williams”), notified Sherwin-Williams of his decision to retire from his position as Executive Chairman, effective as of the close of business on December 31, 2024.
On November 13, 2024, Jane M. Cronin, Senior Vice President – Enterprise Finance (principal accounting officer) (“SVP – Enterprise Finance”) of Sherwin-Williams, notified Sherwin-Williams of her decision to retire from her position as SVP – Enterprise Finance, effective as of the close of business on December 31, 2024.
Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.
Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.
Harlan Weisman, M.D., Kirk Coleman and Zamaneh Mikhak, Ph.D., ceased serving as President/Chief Executive Officer, Chief Financial Officer and Chief Medical Officer, respectively, to be effective as of November 14, 2024.
Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.
Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.
Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.
Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.
Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.
Harlan Weisman, M.D., Robert J. Mills, Stephen Rocamboli, Brandi Roberts, Catherine Lee and Thomas King, each notified the Company of their respective resignations as members of the Board and all committees thereof, effective November 14, 2024.
On November 7, 2024, W. Andrew Adams notified National HealthCare Corporation (the “Company”) that, after 32 years of service, he intends to retire as a member of the Company Board of Directors (the “Board”) effective at the conclusion of the 2025 annual meeting of shareholders to be held on May 8, 2025.
On November 8, 2024, Linda Stacy, Secretary, Principal Financial Officer, and Principal Accounting Officer of National Research Corporation (the “Company”), notified the Company of her decision to retire effective December 31, 2024.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.